Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies

April 29, 2021
OncLive Staff

Dr. Riedel and Dr. Van Tine discuss the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

Welcome to OncLive On AirTM! I’m your host today, Caroline Seymour.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Deciphera Pharmaceuticals, Inc., we had the pleasure of speaking with Richard F. Riedel, MD, associate professor of medicine at Duke Cancer Institute, and Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director of the Sarcoma Program in the Division of Medical Oncology at Washington University School of Medicine in St. Louis, to discuss treatment gaps that have plagued the sarcoma field and research through which investigators are hoping to fill those gaps.

In our exclusive interview, Riedel and Van Tine discussed the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib (Qinlock) in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.